Phase 1Recruiting
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants
- Sponsor
- Shanghai World Leader Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 60 planned
- Conditions
- Overweight; Obesity
- Interventions
- Semaglutide Nasal Spray; Placebo; Semaglutide Injection
- Ages
- adults, older adults
- Registry
- NCT07465965
Full record on ClinicalTrials.gov
From the registry
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
Primary outcomes
- Maximum Plasma Concentration (Cmax)
- Time to maximum concentration(Tmax)
- Area under the concentration-time curve from time 0 to time t (AUC0-t)
- Area under the concentration-time curve from time 0 to infinity(AUC0-∞)
History
Study completion
Primary completion
Registered
Started